Shana Dodge has a diverse work experience in the field of research and psychology. Shana is currently the Director of Research Engagement at The Association for Frontotemporal Degeneration (AFTD) since May 2021. Prior to this, they worked as a Research Psychologist at SAIC from December 2013 to April 2021. Shana also served as a Postdoctoral Resident at the San Diego Va Health Care System from September 2012 to August 2013. Shana gained experience as a Pre-Doctoral Intern at the UCLA Semel Institute for Neuroscience and Human Behavioral from an unspecified time in 2011 to 2012. Before that, they worked as a Therapist and Assessor at the University of Hawaii Center for Cognitive Behavior Therapy from August 2006 to May 2011. Shana's early career includes the role of Clinical Research Coordinator at the Mount Sinai School of Medicine, where they coordinated clinical drug trials and imaging studies involving patients with schizophrenia, handled IRB submissions, and applied for grant submissions and renewals.
Shana Dodge has a strong educational background in the field of psychology. Shana obtained a Bachelor of Arts (B.A.) in Psychology from The George Washington University, where they studied from 2001 to 2004. Shana then pursued a Master of Arts (M.A.) in Psychology from The New School, where they studied from 2004 to 2006. After that, they attended the University of Hawaii at Manoa from 2006 to 2012, where they completed their Doctor of Philosophy (Ph.D.) in Clinical Psychology.
In addition to their academic achievements, Shana Dodge also holds a certification as a Licensed Clinical Psychologist, which they obtained from the California Board of Psychology in November 2013.
The Association for Frontotemporal Degeneration (AFTD)
AFTD establish an institution dedicated to advancing FTD research, providing information, education, and support, as well as raising awareness of this uncommon and especially devastating disease, the AFTD, in whom mission is to improve the quality of life for those affected by FTD and drive research toward a cure, collaborated with a collective ofdedicated FTD care partners and medical professionals. With a committed board of directors, a robust volunteer network, and medical and scientific advisers from the leading experts from across the world, the company has developed into a major international structure on FTD and young onset dementia. AFTD has profited from kind foundation and donor funding, including gifts from the fund.